Adverse Events Related to Kratom Discontinuation and the Utilization of Prescribed Medications During Hospitalization: A 4-year Retrospective Study in Thanyarak Songkhla Hospital, Thailand
Abstract
Objective: The purpose of this study was to investigate adverse events related to kratom cessation and the utilization of prescribed medications during hospitalization.
Material and Methods: This retrospective study was conducted in Thanyarak Songkhla Hospital, Thailand. The study included patients aged 15 years and above who had a history of kratom consumption prior to hospitalization. Adverse events after kratom discontinuation during the patient’s hospital admission were documented. The prescribed drug regimens during hospitalization were recorded.
Results: During the 4-year study period, 81 patients were enrolled. Fifty-four patients (67%) developed adverse events. The majority of enrolled patients were males between the ages of 15 and 34 years. The popular 4x100 kratom cocktail was commonly consumed prior to admission. Musculoskeletal pain (28%) and psychological disorders such as insomnia, agitation, and anxiety were observed as major adverse events. Patients with adverse events received more medications than those without adverse events (p-value=0.02). Typical antipsychotics were commonly prescribed for patients with adverse events related to kratom discontinuation (p-value<0.01).
Conclusion: In hospitalized patients who had consumed kratom previously, 67% experienced adverse events. The most common adverse events were musculoskeletal pain and psychological disorders. In patients with adverse events, antipsychotics were commonly prescribed. A history of kratom consumption should be asked during hospitalization for all admitted patients to assess the possibility of an adverse event and provide appropriate management.
Keywords
Full Text:
PDFReferences
Ponglux D, Wongseripipatana S, Takayama H, Kikuchi M, Kurihara M, Kitajima M, et al. A new indole alkaloid, 7 α-hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand. Planta Med 1994;60:580-1.
Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, et al. Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands. J Med Chem 2002;45:1949-56.
Eastlack SC, Cornett EM, Kaye AD. Kratom–pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther 2020;9:55-69.
Thailand Narcotics Act (25 May, 2021). Ratchakitcha. 138; 2021 [cited 2023 Jan 5]. Available from: http://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/035/T_0001.PDF
Charoenratana S, Anukul C, Aramrattana A. Attitudes towards Kratom use, decriminalization and the development of a community-based Kratom control mechanism in southern Thailand. Int J Drug Policy 2021;95:103197.
Kalayasiri R, Rungnirundorn T, Ali R, Marsden J. Regulation and decriminalisation of illegal substances in Thailand. J Health Sci Med Res 2019;37:157-62.
Prevete E, Kuypers KPC, Theunissen EL, Esposito G, Ramaekers JG, Pasquini M, et al. Clinical implications of Kratom (Mitragyna speciosa) use: a literature review. Curr Addict Rep 2023;10:317-34.
Trakulsrichai S, Tongpo A, Sriapha C, Wongvisawakorn S, Rittilert P, Kaojarern S, et al. Kratom abuse in Ramathibodi Poison Center, Thailand: a five-year experience. J Psychoactive Drugs 2013;45:404-8.
Saingam D, Assanangkornchai S, Geater AF, Lerkiatbundit S. Factor analytical investigation of krathom (Mitragyna speciosa Korth.) withdrawal syndrome in Thailand. J Psychoactive Drugs 2016;48:76-85.
Davidson C, Cao D, King T, Weiss ST, Wongvisavakorn S, Ratprasert N, et al. A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017. Am J Drug Alcohol Abuse 2021;47:74-83.
Tungtananuwat W, Lawanprasert S. Fatal 4x100; home-made kratom juice cocktail. J Health Res 2010;24:43-7.
Kamble SH, Sharma A, King TI, Berthold EC, León F, Meyer PKL, et al. Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicol Lett 2020;319:148-54.
Kamble SH, Sharma A, King TI, León F, McCurdy CR, Avery BA. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica 2019;49:1279-88.
Talek M, Cottler LB, Wichaidit W, Assanangkornchai S. Patterns of kratom use among male drug users in the deep south of Thailand. Thai J Public Health 2021;51:16-24.
Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: a systematic review with case series. J Psychoactive Drugs 2019;51:12-8.
Eaimchaloay S, Kalayasiri R, Prechawit S. Characteristics and physical outcomes of kratom users at a substance abuse treatment center. Chula Med J 2019;63:179-85.
Junsirimongkol B, Singkhorn O, Thipnuruk B, Puanglod D. The study of symptoms of clinical effects in Kratom abusers at the outpatient clinic, Suansaranrom Hospital. J Somdet Chaopraya Inst Psychiat 2009;3:41-52.
Lexicomp Online, Lexi-Drugs Multinational. Waltham. MA: UpToDate, Inc. [cited Feb 23, 2023]. Available from: https://online.lexi.com.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.